We are live on ! Find out more
THNR

Amplify Weight Loss Drug & Treatment ETF

4 hedge funds and large institutions have $1.17M invested in Amplify Weight Loss Drug & Treatment ETF in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital invested

Capital invested by funds: $919K → $1.17M (+$251K)

4.8% more ownership

Funds ownership: 22%26.8% (+4.8%)

0% more funds holding

Funds holding: 44 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
4
Holders Change
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

Rank Fund Capital Flow
1
GS
GTS Securities
Florida
-$240K
2
UBS Group
UBS Group
Switzerland
-$4.75K

THNR Hedge Fund Activity: Q2 2026 in Review

4 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q2 2026, worth a combined $1.17M — up 27% from $919K a quarter earlier.

Fund positioning in THNR was balanced in Q2 2026: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $431K. The largest seller was GTS Securities, exiting entirely with an estimated $240K sold.

  • 4 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $1.17M of Amplify Weight Loss Drug & Treatment ETF stock for Q2 2026, up 27% quarter-over-quarter.
  • 2 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q2 2026 and 2 closed out, a net change of 0 holders.
  • The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q2 2026 was Jane Street, an estimated $431K added.
  • The largest Amplify Weight Loss Drug & Treatment ETF seller in Q2 2026 was GTS Securities, an estimated $240K sold.

Based on aggregated 13F filings for Q2 2026.